At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 26 enrolled
Drug / intervention
Colchicine, 0.6 mg PO BID +1 moredrug
Likely dose
Colchicine, 0.6 mg PO BIDfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Impact and Time Course of Colchicine Therapy on C-reactive Protein Elevation in Chronic Atrial Fibrillation (AF) and Post AF Ablation
In Brief
A Phase 2 clinical trial evaluating Colchicine, 0.6 mg PO BID and Matching placebo for Atrial Fibrillation. Completed, enrolled 26 participants across 1 site.
Detailed Summary
Colchicine will lower C-reactive protein (CRP) in chronic atrial fibrillation and reduce the rise in CRP which occurs following atrial fibrillation ablation
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtrial Fibrillation
CountriesUnited States
CollaboratorsTakeda, Detiger Funds
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedDec 2012
Enrollment StartMar 2013
Primary CompletionDec 2016
TodayJul 2026
First PostedDec 24, 2012
Enrollment StartMar 1, 2013
Primary CompletionDec 6, 2016
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 13.5 years ago
Interventions
Colchicine, 0.6 mg PO BIDdrug
Colchicine tablets will be over-encapsulated by the research pharmacy to be indistinguishable from placebo
Matching placebodrug
Matching placebo tablets will be encapsulated by the research pharmacy to be indistinguishable from active drug